Literature DB >> 3436677

Investigation of the biliary clearances of cefotaxime and desacetylcefotaxime by an original procedure in cholecystectomised patients.

F Jehl1, J D Peter, A Picard, J P Dupeyron, J Marescaux, A Sibilly, H Monteil.   

Abstract

The biliary elimination of cefotaxime (CTX) and its metabolite desacetylcefotaxime (DSCTX) were measured by HPLC in nine recently cholecystectomised patients following the i. v. injection of 15 mg/kg body weight of CTX. All of the bile was collected by an original procedure: the inflated balloon of a Fogarty catheter was introduced into the distal branch of a Kehr drain T-tube. Biliary clearance of CTX and DSCTX was measured for 8 h. Cefotaxime peaked at 90 min after injection at 34.5 +/- 15.3 mg/l; in the 7-8 h sample it was 2.7 +/- 1.7 mg/l. DSCTX peaked at the same time at 49.3 +/- 17.0 mg/l, and was 4.6 +/- 3.2 mg/l at 8 h. The bile/serum ratio of CTX and DSCTX concentrations was above 1 from the first to the eighth hours (range: 1.35 +/- 1.08 to 11.0 +/- 3.1). The biliary clearance of CTX was 0.190 ml/min. The total amounts of CTX and DSCTX eliminated in bile were respectively 1050 +/- 472.8 micrograms and 1902.7 +/- 804.1 micrograms (0.093 +/- 0.041% of the dose and 0.186 +/- 0.077% of the dose). Considering the minimum inhibitory concentration of the pathogens currently encountered in biliary sepsis, CTX should be a suitable antimicrobial agent for the treatment of biliary infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436677     DOI: 10.1007/BF01647231

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography.

Authors:  F Jehl; P Birckel; H Monteil
Journal:  J Chromatogr       Date:  1987-01-23

2.  Cefotaxime concentration in the bile and wall of the gallbladder.

Authors:  C J Soussy; L P Deforges; J Le Van Thoi; W Feghali; J R Daval
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Metabolism of cefotaxime in animals and man.

Authors:  J Chamberlain; J D Coombes; D Dell; J M Fromson; R J Ings; C M Macdonald; J McEwen
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  The influence of third-generation cephalosporins on the aerobic intestinal flora.

Authors:  J P Guggenbichler; J Kofler; F Allerberger
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients.

Authors:  H Knothe; G A Dette; P M Shah
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  [Focus and value of the assay of 5 beta-lactams using high-performance liquid chromatography].

Authors:  F Jehl; H Monteil; R Minck
Journal:  Pathol Biol (Paris)       Date:  1983-05

8.  Investigation of human bile and serum levels by high pressure liquid chromatography after administration of latamoxef or cefotaxime.

Authors:  R Krausse; U Ullmann; G Brandstetter; P Kratochvil
Journal:  Arzneimittelforschung       Date:  1984

9.  Cefotaxime: sites and pathway of metabolic conversion.

Authors:  C M Macdonald; A McDonald; J M Fromson; J D Coombes
Journal:  Arzneimittelforschung       Date:  1984

10.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

View more
  2 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Emergence of cross-resistance to beta-lactam antibiotics in fecal Escherichia coli and Klebsiella strains from neonates treated with ampicillin or cefuroxime.

Authors:  K Tullus; B Berglund; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.